KR20180102431A - Cosmetic composition for anti-aging comprising fucosyllactose - Google Patents

Abstract

The present invention relates to a composition for alleviating skin aging and to a functional cosmetic product for alleviating skin aging. According to the cosmetic composition or the functional cosmetic product according to one aspect, fucosyllactose inhibits the expression of MMP-1, IL-6, and IL-8 and significantly increases the synthesis of collagen, and since the fucosyllactose has no toxicity, the fucosyllactose can be safely used for development of a composition for the alleviating skin aging and functional cosmetics.

Description

[0001] The present invention relates to a cosmetic composition for anti-aging comprising fucosyllactose,

The present invention relates to a composition for improving skin aging and a functional cosmetic for improving skin aging.

Skin is the outermost organ of the body and plays a role in protecting our body from external environment. Therefore, it can be easily attacked because it is exposed to external stimuli more than other organs. Particularly, facial skin is directly exposed to ultraviolet rays and pollutants, and wrinkles easily occur due to aging of the skin.

In general, skin aging is divided into extrinsic aging and endogenous aging. Endogenous aging is also called chronological aging and is mainly caused by the passage of time. On the other hand, extrinsic aging is a phenomenon caused by various external factors, and photoaging due to ultraviolet rays is typical. The wrinkles, elasticity reduction, skin burning and drying phenomena caused by various skin aging factors are mostly caused by changes of extracellular matrix proteins, and are mainly caused by collagen, elastin, It is pointed out as a cause of destruction of hyaluronic acid and the like. Among them, matrix metalloproteinases (MMPs) are known to be representative enzymes for degrading substrate proteins. The activity of MMP is remarkably increased by a single ultraviolet irradiation, and it accelerates the formation of wrinkles by decomposing various substrate proteins including collagen. It is also related to the inflammatory cytokines IL-6 and IL-8, which are known to affect the expression of MMPs by ultraviolet light.

On the other hand, human milk oligosaccharides (HMO) with more than 200 unique structures are present at considerably higher concentrations (5-15 g / L) than other mammalian milk. HMOs have the functionality to provide various biological activities that affect human health, such as prebiotic effects that help the growth of intestinal lactobacilli, prevention of pathogenic infections and control of the immune system. HMO is composed of D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose (Fuc) and Sia (N-acetyl neuraminic acid [Neu5Ac]) . Most HMOs have a lactose (Galβ1-4Glc) residue at the reducing end. Gal of lactose is sialylated in the form of 3-sialyllactose and 6-sialyllactose by α- (2,3) - and α- (2,6) can be fucosylated in the form of 2-fucosyllactose and 3-fucosyllactose, respectively, as? - (1,3) -bonds. To form a complex milk oligosaccharide, N-acetyllactosamine (Galβ1-3 / 4GlcNAc), in which the monomers are repeated, is connected in a linear or branched fashion. Finally, the lactose or polylactosamine skeleton is sialylated by α- (2,3) - and α- (2,6) -linkages or α- (1,2) - and α- - < / RTI > Among them, 2-fucosyllactose has been reported to be the major HMO involved in various biological activities, and it is known to be the most abundant among the oligosaccharides contained in breast milk. Therefore, the availability of 2-fucosyllactose as a material for health foods and foods for medicines for infant formula . However, the effect of improving the wrinkles of fucosyllactose has not yet been elucidated.

To date, vitamins C, α-tocopherol, retinol and derivatives thereof have been used in cosmetics and medicines as a material for wrinkle improvement. However, when they are formulated in formulations, they have a limitation in that they are not removed or chemically stable have. In order to overcome these shortcomings and limitations, the development of a cosmetic composition for wrinkle improvement using natural materials derived from natural materials has recently been spotlighted, and it is necessary to find out these.

Accordingly, the inventors of the present invention have made efforts to overcome the problems of the prior art, and as a result, they have screened a material derived from natural materials inhibiting the expression of MMP-1, a collagenase, and inflammatory cytokines IL-6 and IL- Respectively. Among them, fucosyllactose inhibited collagen degradation by inhibiting the expression of MMP-1, IL-6 and IL-8, confirming that skin aging and wrinkle improving effect were achieved, thereby completing the present invention.

One aspect is to provide a cosmetic composition for improving skin aging comprising fucosyllactose.

Another aspect is to provide a functional cosmetic for improving skin aging comprising the cosmetic composition described above.

Another aspect is to provide a quasi-drug composition for improving skin aging comprising fucosyllactose.

Another aspect is to provide a pharmaceutical composition for improving skin aging comprising fucosyllactose.

Another aspect is to provide a food composition for improving skin aging comprising fucosyllactose.

One aspect provides a cosmetic composition for improving skin aging comprising fucosyllactose.

The fucosyllactose is a type of human milk oligosaccharides (HMO) contained in breast milk, and refers to a trivalent sugar in which fucose is added to lactose.

The term "skin aging" in the present invention refers to changes in type and intangible changes that appear on the skin with age, and includes, for example, a phenomenon in which the skin thickness becomes thin, the number of the dermis, the number of blood vessels, Refers to a reduction in wound healing, skin barrier function, epidermal water retention, sweat secretion, sebum secretion, vitamin D production, physical damage protection, chemical abilities, immune response, sensory function, and body temperature control.

The skin aging may be skin aging caused by an exogenous factor or endogenous factor.

The extrinsic factor refers to various external factors such as ultraviolet rays, and the intrinsic factor is also referred to as a chronological factor, which is mainly caused by the passage of time. Specifically, the skin aging specifically includes not only early symptoms of aging induced by external stimuli such as ultraviolet rays, pollution, smoke, chemicals, etc., but also natural aging phenomena caused by aging of skin cells And is a concept that includes both wrinkles, elasticity reduction, skin burning and drying phenomenon. Also, wrinkles include those in which irritation caused by changes in internal and external factors changes the constituents of the skin tissue to cause wrinkles.

The fucosyllactose improves skin wrinkles. The term "skin" in the present invention refers to a tissue covering the body surface of an animal, and is a concept of the broadest notion including a scalp and hair as well as a tissue covering a body surface such as a face or a body. The term "skin wrinkle improvement" in the present invention means to maintain or enhance the ability of skin to be related to wrinkles and elasticity.

The cosmetic composition of the present invention may contain 0.001% by weight to 50% by weight of fucosyllactose based on the total weight of the cosmetic composition. If the content is less than 0.001% by weight, the wrinkle-improving effect can not be attained. If the content is more than 50% by weight, the formulation may be difficult and the feeling of use may be deteriorated.

The fucosyllactose may be 2-fucosyllactose or 3-fucosyllactose. Specifically, the fucosyllactose may be 2-fucosyllactose, which is the oligosaccharide known to be the most abundant among the oligosaccharides contained in breast milk.

The method for obtaining fucosyllactose is not particularly limited, and it may be derived from breast milk extracted from breast milk, synthesized by a chemical or enzymatic method using a known production method, mass produced using microorganisms, or commercially available.

The fucosyllactose inhibits the expression of MMP-1 (matrix metalloproteinases-1), IL-6 (interleukin-6), or IL-8 (interleukin-8). The fucosyllactose promotes collagen production. As used herein, " collagen " is a protein that occupies the largest part quantitatively and functionally in the human body. It is an extracellular matrix that forms the skeleton of all cells in the human body, more specifically, Means the constituent factor. Human tissues containing large amounts of collagen include bone tissues such as skin, bones and cartilage, tendons, and ligaments. It is known that aging of the tissues causes human aging diseases such as skin wrinkles and sagging and osteoporosis, which is caused by a decrease in collagen amount and function due to decrease of collagen synthesis of tissues.

That is, the fucosyllactose inhibits expression of MMP-1 (matrix metalloproteinases-1), IL-6 (interleukin-6), and IL-8 (interleukin-8) and promotes collagen production, And it has an effect of preventing skin aging.

The cosmetic composition is basically applied to the skin, and can be prepared into any formulation conventionally produced by referring to the cosmetic composition of the related art. More specifically, the present invention relates to a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritional cream, a moisturizing cream, a hand cream, a foundation, , A cleansing lotion, a cleansing cream, a body lotion, and a body cleanser, but the present invention is not limited thereto.

When the formulation of the present invention is a paste, cream or gel, the carrier component may include an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, have.

When the formulation of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like. Especially, in the case of spray, a mixture of chlorofluorohydrocarbons, propane / Propane, dimethyl ether, and the like.

When the formulation of the present invention is a solution or an emulsion, the carrier component may include a solvent, a solubilizing agent, an emulsifying agent and the like. Specific examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid esters of sorbitan, and the like.

When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol, propylene glycol or the like as a carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, trachant, and the like.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, and the like.

The cosmetic composition of the present invention may further contain customary adjuvants and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments, perfumes and the like which are conventionally used. For example, the cosmetic composition may further contain auxiliary components such as glycerin, butylene glycol, polyoxyethylene hardened castor oil, tocopheryl acetate, citric acid, panthenol, squalane, sodium citrate, allantoin, Zero may include hexanediol, purified water, and the like.

Another aspect provides a functional cosmetic for improving skin aging comprising the cosmetic composition described above.

In the present invention, the term "cosmedical, cosmeceutical" refers to a product which has a professional function of medicines introduced into cosmetics, unlike ordinary cosmetics, and has a special function emphasizing physiologically active effects and effects. A product that helps, a product that helps to improve wrinkles, a product that helps protect skin from burns or UV rays.

In the present invention, the functional cosmetic refers to a product which helps to improve the aging of the skin, for example, the wrinkle of the skin among various functional cosmetics. Specifically, it can be a functional cosmetic for improving skin aging including fucosyllactose.

Another aspect provides a quasi-product composition for improving skin aging comprising fucosyllactose.

The term "quasi-drug" in the present invention means a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or an animal, Or products similar to those that are not machinery, and those used for sterilization, insecticide and similar uses for the prevention of infectious diseases, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human or animal. Machinery, or apparatus, and that is not an apparatus, machine or apparatus of an article used for the purpose of causing pharmacological effects on the structure or function of a person or animal.

When the composition of the present invention is used as a quasi-drug additive, the composition may be added as it is or may be used together with other quasi-drugs or quasi-drugs, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.

The quasi-drug composition of the present invention is not limited thereto, but preferably includes a body cleanser, a disinfectant cleaner, a detergent, a kitchen detergent, a cleaning detergent, a toothpaste, a gauze agent, a wet tissue, a detergent, a soap, a hand wash, , A mask, an ointment agent, and a filter filler.

Another aspect provides a pharmaceutical composition for improving skin aging comprising fucosyllactose.

The pharmaceutical composition may further include a pharmaceutically acceptable carrier in addition to the fucosyllactose as an active ingredient.

In the present invention, the above-mentioned "pharmaceutically acceptable" means that it is commonly used in the pharmaceutical field, which does not disturb the biological activity and properties of the compound administered, without irritating the organism upon administration thereof.

The pharmaceutical composition may be formulated together with the carrier to be used as medicines, feed additives, drinking water additives, and the like.

In the present invention, the type of the carrier is not particularly limited and any carrier conventionally used in the art can be used. Examples of the carrier include, but are not limited to, saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, . These may be used alone or in combination of two or more.

In addition, the pharmaceutical composition may be supplemented with other pharmaceutically acceptable additives such as excipients, diluents, antioxidants, buffers or bacteriostats, and may be used as fillers, extenders, wetting agents, disintegrants, dispersants, surfactants, binders Or a lubricant or the like may be additionally used.

The pharmaceutical composition may be formulated into various formulations suitable for oral administration or parenteral administration.

Non-limiting examples of such oral dosage forms include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs .

Binding agents such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin to formulate the pharmaceutical composition for oral administration; Excipients such as dicalcium phosphate and the like; Disintegrating agents such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax may be used, and sweeteners, fragrances, syrups and the like may also be used. .

Furthermore, in the case of capsules, in addition to the above-mentioned substances, liquid carriers such as fatty oils can be further used.

Non-limiting examples of parenteral preparations include injection solutions, suppositories, respiratory inhalation powders, aerosol formulations for spray, ointments, powder for application, oils, creams and the like.

In order to formulate the pharmaceutical composition for parenteral administration, a sterilized aqueous solution, a non-aqueous solvent, a suspending agent, an emulsion, a freeze-dried preparation, an external agent and the like may be used. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, Vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.

More specifically, when the pharmaceutical composition is formulated into an injection, the composition of the present invention is mixed with a stabilizer or a buffer in water to prepare a solution or suspension, which is then used for unit administration of an ampoule or a vial Can be formulated. When the pharmaceutical composition of the present invention is formulated into an aerosol formulation, a propellant or the like may be added together with the additive such that the water-dispersed concentrate or the wet powder is dispersed.

When the pharmaceutical composition is formulated into an ointment, cream, or the like, an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, Can be used as a carrier.

The pharmaceutically effective amount and the effective dose of the pharmaceutical composition may be varied depending on the formulation method, administration method, administration time and / or route of administration of the pharmaceutical composition, Including the type and severity of the disease, the type of subject being treated, the age, body weight, general health, severity or severity of the disease, sex, diet, excretion, drugs used simultaneously or sequentially in the subject, Can be varied according to various factors and similar factors well known in the medical field, and those skilled in the art can easily determine and prescribe effective dosages for the desired treatment.

The dose for a more preferable effect of the pharmaceutical composition may be preferably 1 mg / kg to 1,000 mg / kg per day, more preferably 10 mg / kg to 500 mg / kg per day. Administration of the pharmaceutical composition of the present invention can be administered once a day, or divided into several doses. Accordingly, the dosage is not limited in any way to the scope of the present invention.

The route of administration and the mode of administration of the pharmaceutical composition may be independent of each other, and the method is not particularly limited, and any route of administration and administration method may be used as long as the pharmaceutical composition can reach the desired site . The pharmaceutical composition may be administered orally or parenterally.

The parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration or subcutaneous administration, etc., and a method of applying, spraying or inhalating the composition to a site requiring improvement But are not limited to. Preferably, the pharmaceutical composition of the present invention can be administered in such a manner that it is applied to a site where improvement of skin aging is required.

Another aspect is to provide a food composition for improving skin aging comprising fucosyllactose.

When the food composition is used as a health functional food additive, the composition may be added as it is or may be used in combination with other health functional food or health functional food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use. Generally, the composition of the present invention may be added in an amount of preferably not more than 15 parts by weight, more preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage. However, in the case of long-term intake intended for health control and hygiene, the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.

There is no particular limitation on the kind of the health functional food of the present invention. Examples of the health functional food to which the above food composition can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, , A drink, an alcoholic beverage, and a vitamin complex, and may include foods used as food for animals, which may include all health functional foods in the conventional sense.

In addition, when the food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose, fructose, polysaccharides such as disaccharides such as maltose, sucrose, dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweeteners may be natural sweeteners such as tau martin and stevia extract, and synthetic sweeteners such as saccharin and aspartame.

In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

According to the composition or functional cosmetic according to one aspect, fucosyllactose inhibits the expression of MMP-1, IL-6, or IL-8 and significantly increases the synthesis of collagen. The present invention can be safely applied to the development of a composition for use in the present invention.

Brief Description of the Drawings Fig. 1 shows the results of confirming the inhibitory activity of MMP-1 of 2-fucosyllactose. Fig.
2 is a graph showing the results of confirming the inhibition of IL-6 of 2-fucosyllactose.
3 is a graph showing the results of confirming the inhibitory effect of IL-8 on 2-fucosyllactose.
FIG. 4 is a graph showing the results of confirming the effect of promoting the production of collagen (type Iprocollagen) of 2-fucosyllactose.

Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

Example  One: Fucosyl-lactose  Collagenase inhibitory effect measurement

Fucosyllactose was purchased from Jennewein Biotechnologie in order to measure the collagenase inhibitory effect of fucosyllactose. The purchased material was dissolved in tertiary distilled water as a solubilizer at a concentration of 10 占 퐂 / ml and 100 占 퐂 / ml And used in the following experiments.

Specifically, human fibroblast cell line (Human dermal fibroblast, Hs68) was tested under the following conditions. First and incubated for 24 hours in an incubator of a frequency divider to Hs68 fibroblasts in 96-well plates with 2x10 ⁴ and then, 37 ℃, 5% CO ₂ condition. After the medium was removed, DPBS was added, and the remaining cells except the UVB non-irradiated group were irradiated with UVB at 15 mJ / cm ² , and 2-fucosyllactose was added at different concentrations and further cultured for 24 hours. RNA was isolated from the cells of each sample using triazole (RNA iso, DAKARA, Japan), and RNA was quantitated at 260 nm with nanodrop, and cDNA was synthesized from the amplified RNA using 2 μg of each RNA (C1000 Thermal Cycler, Bio-Rad, USA). Real-time PCR was performed in a real-time PCR machine using a mixture of a target protein, MMP-1 primer and a cyanine dye, SYBR Green supermis (Applied Biosystems, USA) And finally the degree of expression of the MMP-1 gene was confirmed. The expression level of the gene was finally analyzed by correction for the β-actin gene, and the results of the analysis are shown in FIG.

As shown in Fig. 1, it was confirmed that the amount of MMP-1 gene expression was significantly decreased in the 2-fucosyllactose-treated group, whereas the amount of MMP-1 expression was increased in the UVB irradiation group.

Thus, it can be seen that fucosyllactose reduces the expression of MMP-1 which accelerates the formation of wrinkles by decomposing collagen, thereby exhibiting a wrinkle-reducing effect and an anti-aging effect.

Example  2: Fucosyl-lactose  IL- 6 and  Measurement of IL-8 inhibitory effect

In order to evaluate the IL-6 and IL-8 inhibitory effects of 2-fucosyllactose, the same cells as described in Example 1 were used and the experiment was conducted under the same conditions. However, IL-6 and IL-8 primers were used instead of MMP-1 primers in the final real-time PCR. The expression level of the gene was finally analyzed by correction for the β-actin gene and the results of the analysis are shown in FIGS. 2 and 3, respectively.

As shown in FIG. 2 and FIG. 3, it was confirmed that the amount of IL-6 and IL-8 gene expression was decreased in a concentration-dependent manner and in a similar manner as in the case of MMP-1 gene expression in the 2-fucosyllactose-treated group.

Thus, fucosyllactose reduces the expression of IL-6 and IL-8, which are inflammatory cytokines, and thus shows a wrinkle-reducing effect and an anti-aging effect.

Example  3: Fucosyl-lactose  Measurement of promoting collagen production

Experiments were conducted using the same cells as those described in Examples 1 and 2 to measure the stimulatory effect of collagen production in skin cells of 2-fucosyllactose.

The cells were seeded in 96-well plates in the same manner as in Example 1, and then cultured in an incubator at 37 ° C and 5% CO ₂ for 24 hours. Subsequently, the medium containing 2-fucosyllactose (10 μg / ml or 100 μg / ml) or TGF-β was replaced with a medium not containing the efficacious material, and further cultured for 24 hours. After 24 hours, the culture medium was recovered and the amount of procollagen I secreted by the medium was determined using PIP EIA Kit (TAKARA, MK101). The results are shown in Fig.

As shown in Fig. 4, it was confirmed that the amount of procollagen I was significantly increased in the case of treatment with 2-fucosyllactose, compared with untreated cells.

Therefore, it was confirmed that fucosyllactose promotes collagen synthesis, thereby improving wrinkles caused by aging of the skin.

Formulation example  1: Manufacture of Toner

A toner preparation containing fucosyllactose was prepared by a conventional method according to the composition components and composition ratios shown in Table 1 below.

ingredient Content (% by weight) Fucosyllactose 1.0 glycerin 3.0 Butylene glycol 2.0 Polyoxyethylene (60) Hardened castor oil 0.5 Polysorbate 80 0.5 ethanol 10.0 antiseptic a very small amount Spices a very small amount Purified water Balance

Formulation example  2: Preparation of lotion agent

Lotion preparations containing fucosyllactose were prepared in a conventional manner according to the compositional components and composition ratios shown in Table 2 below.

ingredient Content (% by weight) Fucosyllactose 1.0 glycerin 7.0 Butylene glycol 3.0 Glyceryl stearate / phage-100 stearate 1.0 Polysorbate 60 0.5 Sorbitan sesquioleate 0.5 Squalane 3.0 Caprylic / capric triglyceride 5.0 Sheer butter 2.0 Stearyl alcohol 0.5 Stearic acid 0.5 Carboxyl vinyl polymer 0.2 Arginine 0.2 antiseptic a very small amount Spices a very small amount Purified water Balance

Formulation example  3: Manufacture of cream agent

The creams containing fucosyllactose were prepared in a conventional manner according to the compositional components and composition ratios shown in Table 3 below.

ingredient Content (% by weight) Fucosyllactose 1.0 glycerin 7.0 Butylene glycol 5.0 Glyceryl stearate / phage-100 stearate 2.0 Polysorbate 60 0.5 Sorbitan stearate 0.5 Phitosqualan 5.0 Jojoba oil 3.0 Caprylic / capric triglyceride 10.0 Aloe butter 3.0 Wax 1.0 Stearyl alcohol 0.5 Behenyl alcohol 0.5 Stearic acid 0.5 Carboxyl vinyl polymer 0.2 Arginine 0.3 Dimethicone 0.5 antiseptic a very small amount Spices a very small amount Purified water Balance

Claims (13)

A cosmetic composition for improving skin aging comprising fucosyllacatose.
The cosmetic composition according to claim 1, which comprises 0.001% by weight to 50% by weight of fucosyllactose based on the total weight of the cosmetic composition.
The cosmetic composition according to claim 1, wherein the fucosyllactose improves skin wrinkles.
The cosmetic composition according to claim 1, wherein the skin aging is skin aging caused by an extrinsic factor or an endogenous factor.
The cosmetic composition according to claim 1, wherein the fucosyllactose is 2-fucosyllactose.
The cosmetic composition according to claim 1, wherein the fucosyllactose is derived from milk.
The cosmetic composition according to claim 1, wherein the fucosyllactose inhibits the expression of MMP-1, IL-6, or IL-8.
The cosmetic composition according to claim 1, wherein the fucosyllactose promotes collagen production.
The cosmetic composition according to claim 1, wherein the cosmetic composition is at least one selected from the group consisting of a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, Wherein the cosmetic composition has at least one formulation selected from the group consisting of a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion, and a body cleanser.
A functional cosmetic for improving skin aging comprising the cosmetic composition according to any one of claims 1 to 9.
A quasi-product composition for improving skin aging comprising fucosyllactose.
A pharmaceutical composition for improving skin aging comprising fucosyllactose.
A food composition for improving skin aging comprising fucosyllactose.

Images